Skip to Content
Merck
All Photos(4)

Key Documents

L9664

Sigma-Aldrich

Loratadine

≥98% (HPLC), powder

Synonym(s):

4-(8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester, Loratidine

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C22H23N2O2Cl
CAS Number:
Molecular Weight:
382.88
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Quality Level

Assay

≥98% (HPLC)

form

powder

color

white

solubility

DMSO: soluble 50 mg/mL
H2O: insoluble

originator

Schering Plough

storage temp.

2-8°C

SMILES string

CCOC(=O)N1CC\C(CC1)=C2/c3ccc(Cl)cc3CCc4cccnc24

InChI

1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3

InChI key

JCCNYMKQOSZNPW-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Loratadine is a non-sedating histamine H1-receptor antagonist. Shown to inhibit the two-pore domain potassium channel K2P18.1 (also called TRESK or KCNK18).
Non-sedating histamine H1-receptor antagonist.

Features and Benefits

This compound was developed by Schering Plough. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

related product

Product No.
Description
Pricing

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

F M Baroody et al.
Allergy, 55 Suppl 64, 17-27 (2001-04-09)
The primary mechanism of antihistamine action in the treatment of allergic diseases is believed to be competitive antagonism of histamine binding to cellular receptors (specifically, the H1-receptors), which are present on nerve endings, smooth muscles, and glandular cells. This notion
Karsten Weller et al.
Acta dermato-venereologica, 93(2), 168-174 (2012-10-12)
Non-sedating H1-antihistamines are the recommended first-line treatment for chronic spontaneous urticaria. While efficacy studies usually apply continuous daily treatment regimens, many patients take their medication on demand. In this randomized, double-blind trial we tested whether on-demand H1-antihistamine desloratadine in standard
P Deep et al.
Synapse (New York, N.Y.), 34(4), 313-318 (1999-10-26)
The efficacy of amantadine in alleviating motor symptoms of Parkinson's disease may be mediated in part by stimulation of cerebral dopa decarboxylase (DDC) activity, secondary to antagonism of N-methyl-D-aspartate (NMDA) type glutamate receptors. We tested the specific hypothesis that amantadine
F Estelle R Simons et al.
The Journal of allergy and clinical immunology, 110(5), 777-783 (2002-11-06)
The extent of the distribution of H(1)- antihistamines into the skin and H(1)-antihistamine activity in the skin are clinically relevant in the treatment of allergic skin disorders. In a prospective, randomized, double-blind, parallel-group, multiple-dose study, we gave fexofenadine 180 mg
M Magerl et al.
The British journal of dermatology, 166(5), 1095-1099 (2012-01-17)
Cold urticaria is a rare but severe and potentially lethal condition. It is primarily treated symptomatically with H(1) -antihistamines. However, patients have a variable response to these drugs and, to date, it has not been possible to predict readily the

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service